Published in AIDS Weekly, December 2nd, 2002
Filing of the NDA is recognition by the FDA that the application is sufficiently complete for review.
"We are very pleased with this notification," commented Daniel G. Welch, chairman and CEO of Triangle. He continued, "Consistent with our previous guidance when we submitted our NDA, the FDA granted Coviracil a standard review. This means that as early as the third quarter of 2003, we hope to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.